Best Gene Therapy CDMOs in Europe

· updated as new inspection, certificate, and trial data enters the platform

Gene Therapy manufacturers on CDMO Signal: 28 listed with manufacturing sites in Europe. 6 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Novartis (in-house manufacturer, Signal Score 85.4), Takeda (also makes its own products, Signal Score 83.4) and AGC Biologics (Signal Score 79.9). Outside that set, higher Signal Scores on this list include FUJIFILM Diosynth Biotechnologies (Signal Score 86.7), Charles River Laboratories (Signal Score 86.3) and ReciBioPharm (Signal Score 82.9). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Gene Therapy CDMOs in Europe with the most regulatory evidence on file

Novartis
85.4
Basel, Switzerland
17 FDA inspections · 51 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-24 · NAI
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Takeda
83.4
Boston, MA · Zurich, CH
4 FDA inspections · 20 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-10 · NAI
See the evidence →
Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
28
CDMOs tracked
27
Fully scored
9
With FDA records
56
FDA inspections
206
EMA/MHRA GMP certs

Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.

The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 24 NAI (no action), 32 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (52), Austria (39), UNITED KINGDOM (36), United States (34), Germany (22).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
4
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
5
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
6
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
7
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
8
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
9
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
10
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
11
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
12
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
13
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
14
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
15
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
16
VG
San Sebastián, Spain
Hiring · 3 open roles
76.8 100.0 0 insp · 4 GMP None on file Available —
17
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
18
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
19
RT
Rome, IT
Fully evidenced
71.1 100.0 0 insp · 4 GMP None on file — 1 program
20
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
21
RA
Stockholm, Sweden
63.0 — — None on file — —
22
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
61.8 — — None on file — 10 programs
23
AM
Gerenzano, Italy
59.0 — — None on file — —
24
CV
Cologne, Germany
56.5 — — None on file — —
—
Germany
Profiled — 2 insp · 2 GMP 2023-09-08 · VAI — —
How we score CDMOs →

What to evaluate in a Gene Therapy CDMO

Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Gene Therapy CDMOs?
Among Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Novartis, Takeda, AGC Biologics. The table above is the full list. CDMOs cannot pay to change a score.
How many Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 9 Gene Therapy CDMOs with FDA inspection records and 206 EMA/MHRA GMP certificates across the group.
What should I look for in a gene therapy CDMO?
Match the vector platform to your program first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, analytics maturity for that vector type, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific detail.
How many gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of AAV, lentiviral, adenoviral, and generally-tagged gene therapy manufacturers. Each is scored independently on the standard four-pillar Signal Score. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Cell & Gene Therapy Viral Vector